Solid Biosciences

Update in progress

SLDB (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Solid Biosciences develops therapies for neuromuscular and cardiac diseases. Its lead candidate, SGT-003, is in Phase 1/2 for Duchenne muscular dystrophy. SGT-212 targets Friedreich’s ataxia in Phase 1b. SGT-501, SGT-601, SGT-401, and SGT-701 are in preclinical or discovery stages for various cardiomyopathies and rare diseases. The company also builds platform technologies, including capsid libraries, genetic regulators, immunomodulation, and multi-gene packaging. Partners include Ultragenyx and universities. Founded 2013, headquartered in Charlestown, MA.

Company score

Sentiment: 0.33; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive